3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Gubra AS's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 2,935.97%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Gubra AS's 3-Year ROIIC % or its related term are showing as below:
STU:PI3's 3-Year ROIIC % is ranked better than 97.8% of 1318
companies
in the Biotechnology industry
Industry Median: -4.63
vs STU:PI3: 2935.97
Gubra AS (STU:PI3) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Gubra AS 3-Year ROIIC % Related Terms
Gubra AS 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Gubra AS's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PI3 vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Gubra AS's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Gubra AS's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Gubra AS (STU:PI3) has a 3-Year ROIIC % of 2,935.97 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Gubra AS and its competitors. According to the industry distribution chart, Gubra AS ranks #29 out of 1318 companies in the Biotechnology industry, placing it in the top 2.2%.
Is Gubra AS's 3-Year ROIIC % too high?
Gubra AS's current 3-Year ROIIC % is 2,935.97. Based on the distribution chart, Gubra AS ranks #29 out of 1318 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gubra AS has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #29 out of 1318 companies for 3-Year ROIIC %. This places Gubra AS in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Gubra AS and its competitors. Gubra AS's current 3-Year ROIIC % is 2,935.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (STU:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €383.88, compared to a current price of €46.00 — trading 88% below its estimated fair value. The current 3-Year ROIIC % is 2,935.97. Gubra AS's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Gubra AS (STU:PI3), the current 3-Year ROIIC % is 2,935.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (STU:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of €46.00 is trading 88% below its estimated GF Value™ of €383.88.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for STU:PI3:
3-Year ROIIC %: 2,935.97
GF Value™: €383.88 vs. price of €46.00 (88% below fair value)
No single metric tells the full story. See the STU:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
56GF Score
Get the complete analysis for STU:PI3
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PI3 has been successfully added to your 
